Sugi Predict
/ Targets
/ FRK
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to FRK by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. |
PHASE3 | COMPLETED |
| A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer |
PHASE2 | WITHDRAWN |
| SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme |
PHASE2 | UNKNOWN |
| Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients |
PHASE2 | ENROLLING_BY_INVITATION |
| First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC |
PHASE2 | UNKNOWN |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy |
PHASE2 | COMPLETED |
| Study in Adult Ph-positive ALL |
PHASE2 | UNKNOWN |
| Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer |
PHASE2 | COMPLETED |
| Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer |
PHASE2 | COMPLETED |
| Neoadjuvant GW572016 to Treat Breast Cancer |
PHASE2 | COMPLETED |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations |
PHASE1/PHASE2 | RECRUITING |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
PHASE1/PHASE2 | COMPLETED |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
PHASE2 | COMPLETED |
| A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase II Study of Vandetanib in Individuals With Kidney Cancer |
PHASE2 | COMPLETED |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations |
PHASE2 | COMPLETED |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer |
PHASE2 | RECRUITING |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors |
PHASE1 | COMPLETED |
| Nilotinib in Huntington's Disease |
PHASE1 | UNKNOWN |
| Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD |
PHASE1 | COMPLETED |
| Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 |
PHASE1 | COMPLETED |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers |
PHASE1 | COMPLETED |
| Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma |
PHASE1 | COMPLETED |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA |
nan | RECRUITING |
| The Development of Human Immunologic Assays Specific to Folate Receptor Antigen |
nan | UNKNOWN |
| Prospective Monocentric Clinical-biological Database |
nan | RECRUITING |
| Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) |
nan | COMPLETED |
| Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a FRK binder may also engage these)